{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Foy V"],"funding":["Cancer Research UK"],"pagination":["1653-1665"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8107738"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(4)"],"pubmed_abstract":["<h4>Background</h4>Circulating tumour cell (CTC) number is an independent prognostic factor in patients with small cell lung cancer (SCLC) but there is no consensus on the CTC threshold for prognostic significance. We undertook a pooled analysis of individual patient data to clinically validate CTC enumeration and threshold for prognostication.<h4>Methods</h4>Four European cancer centres, experienced in CellSearch CTC enumeration for SCLC provided pseudo anonymised data for patients who had undergone pre-treatment CTC count. Data was collated, and Cox regression models, stratified by centre, explored the relationship between CTC count and survival. The added value of incorporating CTCs into clinico-pathological models was investigated using likelihood ratio tests.<h4>Results</h4>A total of"],"journal":["Translational lung cancer research"],"pubmed_title":["EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer."],"pmcid":["PMC8107738"],"funding_grant_id":["19278"],"pubmed_authors":["Terstappen L","Perrone F","Carmel A","Rossi E","Michiels S","Foy V","Morabito A","Lindsay CR","Farace F","Blackhall F","de Luca A","Hiltermann TJN","Groen HJM","Fernandez-Gutierrez F","Faivre-Finn C","Normanno N","Krebs MG","Besse B","Renehan A","Priest L","Carter M","Dive C"],"additional_accession":[]},"is_claimable":false,"name":"EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer.","description":"<h4>Background</h4>Circulating tumour cell (CTC) number is an independent prognostic factor in patients with small cell lung cancer (SCLC) but there is no consensus on the CTC threshold for prognostic significance. We undertook a pooled analysis of individual patient data to clinically validate CTC enumeration and threshold for prognostication.<h4>Methods</h4>Four European cancer centres, experienced in CellSearch CTC enumeration for SCLC provided pseudo anonymised data for patients who had undergone pre-treatment CTC count. Data was collated, and Cox regression models, stratified by centre, explored the relationship between CTC count and survival. The added value of incorporating CTCs into clinico-pathological models was investigated using likelihood ratio tests.<h4>Results</h4>A total of","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-18T14:19:12.343Z","creation":"2025-04-04T21:24:38.765Z"},"accession":"S-EPMC8107738","cross_references":{"pubmed":["34012782"],"doi":["10.21037/tlcr-20-1061"]}}